Ibis Labs
Ibis Labs8About
What does Ibis Labs do?
Ibis.ai delivers advanced clinical language understanding, empowering healthcare institutions to act on valuable information within unstructured medical data. Their data-driven NLP models learn from real-life examples and user interactions, focusing on interpretable AI to suggest ICD-10 codes and match natural language to SNOMED CT concepts. This technology aims to improve accuracy, streamline workflows, and foster innovation for better patient outcomes.
Where is Ibis Labs headquartered?
Ibis Labs is headquartered in Israel.
When was Ibis Labs founded?
Ibis Labs was founded in 2026.
What industry does Ibis Labs operate in?
Ibis Labs operates in HealthTech, MedTech, AI-Driven Drug Discovery, Clinical Trials, Digital Twin Healthcare, Foundation Model.
Building a mental health app focused on emotional well-being and self-care.
A free platform offering mental health tests and AI-powered self-help tools for anonymous mental well-being checks.
An AI copilot for doctors that provides immediate, evidence-based answers to clinical questions from peer-reviewed medical sources.
6dvc is developing usable, scalable, and accurate AI agents for healthcare, specifically focusing on cardiovascular care transformation.
Lymesignal is an AI-assisted platform that transforms publicly available Lyme disease discussions into organized, searchable community knowledge.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
A science-based digital program and app designed to help adults manage ADHD symptoms and build coping skills.
Aetios AI builds advanced clinical tools for mental health professionals, leveraging AI for psychological formulation and treatment planning.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 17 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.